Ependymoma is a brain cancer that occurs during childhood and is usually resistant to cytotoxic therapy. Molecular profiling has helped in better understanding the mechanisms behind the disease and has unveiled EPH receptor B2 (EPHB2) as a critical player in driving disease.

Chinese scientists have been the first to show that combining anti-cancer poly [ADP-ribose] polymerase (PARP) inhibitors with radiotherapy may be effective for treating ependymoma CNS tumors expressing elevated levels of the protein chromosome X open reading frame 67 (CXorf67).